IntroductionTaxine alkaloids cause fatal poisoning, in particular due to the compound’s toxic effect on the cardiovascular apparatus.Case presentationWe describe the case of a 39-year-old Caucasian man with common yew intoxication for whom cardiopulmonary resuscitation using all available methods, although delayed and extended, was successful.ConclusionsExtended and delayed cardiopulmonary resuscitation can be used successfully to treat common yew intoxication.
Prospektivní multicentrická kohortová studie RE-VERSE AD zkoumala účinek podávání idarucizumabu u 2 skupin pacientů antikoagulovaných dabigatranem -ve skupině A u pacientů s nekontrolovatelným, nebo život ohrožujícím krvácením, ve skupině B u pacientů, kteří podstupují akutní chirurgický zákrok. V rámci studie bylo ke zrušení antikoagulačního účinku dabigatranu pacientům intravenózně podáno 5 g antidota rozdělených do 2 dávek po 2,5 g během 15 min. Na sérii kazuistik popisujeme užití léku idarucizumab ve studii RE-VERSE AD a v klinické praxi v období let 2015-2016 ve Fakultní nemocnici Hradec Králové. Uvedené příklady dokumentují výhodu dabigatranu, který má jako dosud jediný lék ze skupiny přímých perorálních antikoagulancií antidotum.Klíčová slova: antidotum -dabigatran -DOAC -idarucizumab -krvácení -operační zákrok -přímá perorální antikoagulancia -vysoké riziko krvácení More safe anticoagulant treatment -use of idarucizumab (Praxbind®): case reports from RE-VERSE AD study and clinical practiceSummary RE-VERSE AD, a prospective multicentric cohort study, examined the effect of idarucizumab on 2 cohorts of patients anticoagulated with dabigatran -in cohort A in patients with uncontrollable or life threatening bleeding, in cohort B in patients who undergo acute surgery. Within the study patients were intravenously administered 5 g antidote divided into 2 doses per 2.5 g within 15 min to eliminate the anticoagulation effect of dabigatran. A series of case studies is presented to describe the use of idarucizumab within the RE-VERSE AD study and in clinical practice in the period of 2015-2016 at the University Hospital Hradec Králové. The included examples illustrate the benefit of dabigatran as the only drug so far from the group of direct oral anticoagulants which has an antidote.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.